9.63
전일 마감가:
$9.54
열려 있는:
$9.34
하루 거래량:
292.77K
Relative Volume:
0.64
시가총액:
$334.61M
수익:
$85.23M
순이익/손실:
$2.70M
주가수익비율:
153.34
EPS:
0.0628
순현금흐름:
$20.97M
1주 성능:
+5.48%
1개월 성능:
+7.84%
6개월 성능:
-9.58%
1년 성능:
-25.81%
Delcath Systems Inc Stock (DCTH) Company Profile
명칭
Delcath Systems Inc
전화
(518) 743-8892
주소
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Compare DCTH vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
DCTH
Delcath Systems Inc
|
9.63 | 334.61M | 85.23M | 2.70M | 20.97M | 0.0628 |
|
ABT
Abbott Laboratories
|
102.87 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
331.54 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
86.63 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
62.82 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
81.05 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-28 | 개시 | Craig Hallum | Buy |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2022-07-26 | 재개 | Canaccord Genuity | Buy |
| 2021-12-10 | 개시 | H.C. Wainwright | Buy |
| 2021-03-09 | 개시 | Canaccord Genuity | Buy |
| 2021-01-05 | 개시 | BTIG Research | Buy |
| 2020-06-01 | 개시 | Laidlaw | Buy |
모두보기
Delcath Systems Inc 주식(DCTH)의 최신 뉴스
EBIT per share of Delcath Systems, Inc. – MUN:DV3R - TradingView
DCTH PE Ratio & Valuation, Is DCTH Overvalued - Intellectia AI
Stock List: Research Stocks from Around the World - GuruFocus
DV3R.SG,0P0000X679,0 (DV3R.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2025 earnings call transcript - MSN
Responsive Playbooks and the DCTH Inflection - Stock Traders Daily
Delcath Systems Inc. (US24661P8077.SG) Balance Sheet - Yahoo! Finance Canada
Delcath (NASDAQ: DCTH) seeks approval to expand 2020 equity incentive plan - stocktitan.net
Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting - BioSpace
Delcath Systems (DCTH) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Decliners Report: What are the future prospects of Delcath Systems IncProduct Launch & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Are options traders betting on a big move in Delcath Systems stock? - MSN
Uveal Neoplasms Markets, Companies, and Investment Opportunities Analysis 2026-2030 - GlobeNewswire
Delcath Systems, Inc. (NASDAQ:DCTH) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Q3 2025 Delcath Systems Inc Earnings Call Transcript - GuruFocus
Risk Analysis: Is Delcath Systems Inc backed by strong institutional buyingForecast Cut & Daily Stock Trend Watchlist - baoquankhu1.vn
Market Catalysts: What is BDSXs 5 year growth outlookTrade Analysis Report & Safe Entry Zone Tips - baoquankhu1.vn
Understanding the Setup: (DCTH) and Scalable Risk - Stock Traders Daily
FRA:DV3R PB Ratio: 2.85 — 49% Below Median - GuruFocus
Form 13G DELCATH SYSTEMS For: 20 March By Investing.com - Investing.com Australia
Daniel Kaufman reports 5.08% stake in Delcath Systems (DCTH) - Stock Titan
Divisadero Street Capital Management LP Invests $5.12 Million in Delcath Systems, Inc. $DCTH - MarketBeat
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $250,000 from Inve - Yahoo
The Technical Signals Behind (DCTH) That Institutions Follow - Stock Traders Daily
Delcath Systems Charts Profitable Path Amid Heavy Investment - The Globe and Mail
Delcath Systems Q3 2025 Earnings Preview - MSN
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Delcath Systems (DCTH) - The Globe and Mail
Delcath Systems, Inc. (DCTH) Surpasses Q2 Earnings and Revenue Estimates - MSN
Can Delcath Systems Inc expand into new marketsQuarterly Earnings Report & Risk Managed Trade Strategies - baoquankhu1.vn
Insider Buying: Sandra Pennell Acquires Shares of Delcath Systems Inc (DCTH) - GuruFocus
Delcath Systems (DCTH) CFO purchases 5,533 common shares at $9.04 - Stock Titan
Fundamentals Check: Is Delcath Systems Inc a strong candidate for buy and holdMarket Performance Report & Accurate Intraday Trading Signals - baoquankhu1.vn
Propel Bio Management LLC Buys 212,457 Shares of Delcath Systems, Inc. $DCTH - MarketBeat
Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology - Yahoo Finance
HC Wainwright Lowers Earnings Estimates for Delcath Systems - MarketBeat
Delcath announces publication of liver cancer treatment trial - Investing.com
Delcath announces publication of liver cancer treatment trial By Investing.com - Investing.com Canada
Delcath Highlights CHOPIN Phase 2 Results in Uveal Melanoma - TipRanks
Insider Buying: Gerard Michel Acquires Additional Shares of Delc - GuruFocus
CHOPIN uveal melanoma trial data in Lancet boosts Delcath (Nasdaq: DCTH) - Stock Titan
[Form 4] DELCATH SYSTEMS, INC. Insider Trading Activity - Stock Titan
Delcath Systems announces publication of Chopin clinical trial results in The Lancet Oncology - marketscreener.com
Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2025 Earnings Call Transcript - Insider Monkey
Delcath Systems Announces Publication Of Chopin Clinical Trial Results In The Lancet Oncology - TradingView
Liver-directed therapy plus immunotherapy extends survival in uveal melanoma - Stock Titan
FY2029 EPS Forecast for Delcath Systems Decreased by Analyst - MarketBeat
Delcath Systems Reports Record 2025 Results, Outlines 2026 Growth Plan - National Today
Delcath: Fundamentals Intact, Despite Share Price Weakness (NASDAQ:DCTH) - Seeking Alpha
Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Uveal Melanoma Treatment Market Set to Soar: Breakthrough - openPR.com
DCTH Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Delcath Systems Inc (DCTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):